- In July 2022, Optinose announced the results of pre-planned analyses from the ReOpen trial program, which evaluated XHANCE for treating chronic sinusitis patients. XHANCE is a drug-device combination that pairs fluticasone propionate nasal spray with Optinose's proprietary Exhalation Delivery System (EDS), designed to deliver medication deep into the nasal passages. This innovative delivery system aims to provide effective anti-inflammatory treatment for chronic sinusitis by targeting the upper nasal airways more precisely
- In August 2021, GlaxoSmithKline received approval from the U.S. Food and Drug Administration for Nucala (mepolizumab) as a treatment for chronic rhinosinusitis with nasal polyps. Nucala, an injectable monoclonal antibody, works by targeting and inhibiting interleukin-5, a key protein involved in the inflammation associated with this condition. This approval offers a new treatment option for patients with chronic rhinosinusitis and nasal polyps, addressing an unmet need in managing severe cases
